We joined Jean Bourhis at ESMO 2019 to learn a little more about the oral antagonist of inhibitor of apoptosis proteins (IAPs), Debio 1143, which is thought to act as a chemo-radio-sensitizer to enhance treatment efficacy.
Questions
1. Please outline the current burden of head and neck cancer? (00:06)
2. Debio 1143 is currently under investigation for head and neck cancer, amongst several other cancers – please describe how this compound works? (00:44)
3. A Phase II trial of Debio 1143 in patients with head and neck cancer recently concluded, what were the key results and what is their potential impact? (01:21)
4. What are the next steps in the development of Debio 1143 for head and neck cancer? (01:55)
Jean Bourhis has participated in advisory boards for Merck, MSD, BMS and AstraZeneca.
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.